DK3173102T3 - FGFR-FC-fusionsprotein og anvendelse deraf - Google Patents

FGFR-FC-fusionsprotein og anvendelse deraf Download PDF

Info

Publication number
DK3173102T3
DK3173102T3 DK16205128.8T DK16205128T DK3173102T3 DK 3173102 T3 DK3173102 T3 DK 3173102T3 DK 16205128 T DK16205128 T DK 16205128T DK 3173102 T3 DK3173102 T3 DK 3173102T3
Authority
DK
Denmark
Prior art keywords
fgfr
fusion protein
fusion
protein
Prior art date
Application number
DK16205128.8T
Other languages
Danish (da)
English (en)
Inventor
Jianmin Fang
Dong Li
Original Assignee
Remegen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remegen Ltd filed Critical Remegen Ltd
Application granted granted Critical
Publication of DK3173102T3 publication Critical patent/DK3173102T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK16205128.8T 2011-05-20 2012-05-18 FGFR-FC-fusionsprotein og anvendelse deraf DK3173102T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201110132218A CN102219860B (zh) 2011-05-20 2011-05-20 FGFR-Fc融合蛋白及其用途
EP12788998.8A EP2711376B1 (en) 2011-05-20 2012-05-18 Fgfr-fc fusion protein and use thereof

Publications (1)

Publication Number Publication Date
DK3173102T3 true DK3173102T3 (da) 2020-02-24

Family

ID=44776585

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16205128.8T DK3173102T3 (da) 2011-05-20 2012-05-18 FGFR-FC-fusionsprotein og anvendelse deraf

Country Status (11)

Country Link
US (2) US9273137B2 (https=)
EP (2) EP3173102B1 (https=)
JP (1) JP2014513941A (https=)
KR (2) KR20130119978A (https=)
CN (1) CN102219860B (https=)
AU (1) AU2012261412B2 (https=)
BR (1) BR112013022285B1 (https=)
CA (1) CA2834584C (https=)
DK (1) DK3173102T3 (https=)
RU (1) RU2560573C2 (https=)
WO (1) WO2012159550A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
WO2014018673A2 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
SG10201703977UA (en) * 2013-05-23 2017-06-29 Five Prime Therapeutics Inc Methods of treating cancer
PT3102577T (pt) * 2014-02-07 2018-10-23 Principia Biopharma Inc Derivados de quinolona como inibidores do recetor do fator de crescimento de fibroblastos
CN105983093A (zh) * 2015-02-11 2016-10-05 烟台荣昌生物工程有限公司 血管新生因子融合蛋白在制备用于治疗与血管新生相关的眼部疾病药物中的应用
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
JP7247097B2 (ja) * 2017-03-17 2023-03-28 バクシム アクチェンゲゼルシャフト がん免疫療法のための新規pd-l1標的dnaワクチン
AU2019394227B2 (en) 2018-12-07 2023-04-06 Remegen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
CN116143941B (zh) * 2022-09-08 2024-06-04 浙江省血液中心 一种KIR3DL1-IgG-Fc融合重组蛋白、应用及试剂盒
CN116199744B (zh) * 2023-03-23 2024-06-25 湖南中晟全肽生物科技股份有限公司 一种结合fgfr2受体的多肽及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
DE102005007665A1 (de) * 2005-02-19 2006-08-31 Degussa Ag Folie auf Basis eines Polyamidblends
EP2083081A1 (en) * 2005-07-22 2009-07-29 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with FGFR fusion proteins
JP2009539412A (ja) * 2006-06-12 2009-11-19 レセプター バイオロジックス, インコーポレイテッド 汎細胞表面レセプター特異的な治療薬
RU2341198C2 (ru) * 2006-11-27 2008-12-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ оценки ангиогенных факторов при химиотерапии рака молочной железы
ZA200903134B (en) * 2006-11-28 2010-08-25 Centelion Modified soluble FGF receptor FC fusions with improved biological activity
AR063975A1 (es) * 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
EP2318529B1 (en) * 2008-08-04 2017-10-18 Five Prime Therapeutics, Inc. Fgfr extracellular domain acidic region muteins
LT2498799T (lt) * 2009-11-13 2016-11-10 Five Prime Therapeutics, Inc. Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途

Also Published As

Publication number Publication date
BR112013022285A2 (pt) 2016-12-06
CN102219860A (zh) 2011-10-19
US20160176945A1 (en) 2016-06-23
US20130195864A1 (en) 2013-08-01
WO2012159550A1 (zh) 2012-11-29
KR20160011241A (ko) 2016-01-29
EP2711376A1 (en) 2014-03-26
BR112013022285B1 (pt) 2020-05-12
EP3173102A1 (en) 2017-05-31
CA2834584A1 (en) 2012-11-29
US9273137B2 (en) 2016-03-01
EP2711376A4 (en) 2015-06-03
EP2711376B1 (en) 2018-07-25
JP2014513941A (ja) 2014-06-19
KR20130119978A (ko) 2013-11-01
RU2013140184A (ru) 2015-07-10
EP3173102B1 (en) 2019-11-20
CN102219860B (zh) 2012-09-12
AU2012261412A1 (en) 2013-08-29
CA2834584C (en) 2019-05-14
AU2012261412B2 (en) 2016-02-25
KR101660336B1 (ko) 2016-09-27
RU2560573C2 (ru) 2015-08-20

Similar Documents

Publication Publication Date Title
IL288203B (en) Meditopes and meditope-binding antibodies and uses thereof
DK3321287T3 (da) Fusionsproteiner og kombinationsvacciner
HRP20150241T1 (xx) Antikancerogeni fuzijski protein
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
CO7020851A2 (es) Proteínas y péptidos modificados
DK2920313T3 (da) Rekombinante adenovira og anvendelse deraf
HUE046156T2 (hu) Szerpin fúziós polipeptidek és alkalmazásuk módszerei
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
HUE054437T2 (hu) Anti-CGRP készítmények és alkalmazásuk
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
DK3333188T3 (da) Anti-NGF-antistoffer og deres anvendelse
DK2920197T3 (da) Prolinlåste sammenhæftede peptider og anvendelser deraf
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
BR112015003838A2 (pt) formulações de anticorpo e proteína
IL232247A0 (en) Polypeptide constructs and uses thereof
ME03075B (me) Prolaktin receptor vezujući proteini i njihova upotreba
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
DK2785375T3 (da) Anti-pd-l1-antistoffer og anvendelser deraf
IL231777B (en) Antibodies against tl1a and uses thereof
DK2812443T3 (da) Cd47-antistoffer og fremgangsmåder til anvendelse deraf
DK2552434T3 (da) Peptider og anvendelse deraf